management of acute exacerbations of copd in 2020
TRANSCRIPT
![Page 1: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/1.jpg)
Management of acute exacerbations of COPD in 2020
Mona Bafadhel
MBChB, PhD, FRCP
Associate Professor Respiratory Medicine
Consultant Respiratory Physician
University of Oxford
![Page 2: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/2.jpg)
Objectives
1. Defining an exacerbation• Known causes
• Potential causes
2. Outcomes following an exacerbation• Following hospital admission
• Long term outcomes
3. Treatments• What the guidelines say
• What the evidence shows
4. Emerging futures
![Page 3: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/3.jpg)
A clinical case
• MR C.• 75 year old• Ex smoker – with pack year history of 56 • Airflow limitation with FEV 43% predicted, obstructive spirometry (ratio 35%) with
significant hyperinflation (RV235%).• On triple inhaled therapy.• On mucolytics.• 3 courses of prednisolone and 2 courses of antibiotics in last 12 months• 1 episode of short hospitalisation (4 days) 1 month ago.
• Presents with worsening dyspnoea. Afebrile. Saturations 93% on air (PaO2 8.2KPa/PaCO2 4.3KPa)
• CXR: no consolidation, ECG: sinus tachycardia, No sputum
![Page 4: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/4.jpg)
1. Defining an exacerbation
![Page 5: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/5.jpg)
Exacerbations of COPD
• Responsible for winter bed pressures in the UK
• Cost the NHS over £500 million annually1
• Over 1.5 million GP consultations annually in UK related to exacerbation1
1. NICE
![Page 6: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/6.jpg)
Exacerbations of COPD
• Responsible for winter bed pressures in the UK
• Cost the NHS over £500 million annually2
• Over 1.5 million GP consultations annually in UK related to exacerbation1
Definition:
‘an acute and sustained worsening of symptoms that require additional treatment’2
• Treated with systemic corticosteroids and antibiotics (unselectively)
1. NICE; 2. http://goldcopd.org;
![Page 7: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/7.jpg)
Exacerbation definitions
• Unchanged definition for 185 years: René LaennecA Treatise on the Diseases of the Chest and on Mediate Auscultation (translated by JForbes). (‘Traité de l’’auscultation médiate et des maladies des poumons et du Coeur’).1835
![Page 8: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/8.jpg)
Causes of an acute deterioration
• Multi-factorial– Bacteria
– Virus
– Airway inflammation
– Others– Pulmonary embolism
– Cardiac instability
– Anxiety
Bafadhel et al, AJRCCM 2011
![Page 9: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/9.jpg)
Biologically different exacerbation clusters
IL5
TNFɑ
IFNɣ
Bafadhel et al. AJRCCM 2011: 184: 662-71
![Page 10: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/10.jpg)
Specific biomarkers to identify exacerbation clusters
Bafadhel et al. AJRCCM 2011: 184: 662-71
![Page 11: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/11.jpg)
2. Outcomes following an exacerbation
![Page 12: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/12.jpg)
Outcomes following an exacerbation are poor
• In-patient mortality is as high at 10%1
• 30 and 90 day readmission rates high1
1. BTS National COPD Audit
![Page 13: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/13.jpg)
Outcomes following an exacerbation are poor
• In patient mortality is as high at 10%1
• 30 and 90 day readmission rates high1
Survival at 5 years is between 30-50%
following a severe event2,3
1. BTS National COPD Audit; 2. Suissa et al. Thorax 2012;67: 957-963; 3. Soler-Cataluna et al. Thorax 2005; 60: 925-931
Figure adapted from Suissa S, et al. Thorax 2012;67:957–63
![Page 14: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/14.jpg)
3. Treatments
![Page 15: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/15.jpg)
3. Treatments
• NICE recommendations NG115 (2018)• Unless contraindicated
• Oral prednisolone 30mg for 5 days for everyone admitted to hospital
• Consider oral prednisolone (at above dose) for patients in the community where dyspnoea is affecting activity of daily living
![Page 16: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/16.jpg)
3. Treatments
• NICE recommendations NG115 (2018)• Unless contraindicated
• Oral prednisolone 30mg for 5 days for everyone admitted to hospital
• Consider oral prednisolone (at above dose) for patients in the community where dyspnoea is affecting activity of daily living
• Consider antibiotics in the context of the following:• Severity of the symptoms, especially sputum purulence
• Previous sputum cultures and sensitivities• First, second and alternative choice of antibiotics listed in table 1 of NG114
![Page 17: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/17.jpg)
Antibiotics in COPD exacerbations
• Cochrane review of 19 RCT’s
• Primary outcomes• Treatment failure episodes
• Secondary outcomes• Mortality, length of hospital stay, time to next exacerbation
0
10
20
30
40
50
60
70
Outpatient In-patient ICU
Setting
Setting
1. Vollenweider et al. Cochrane Database Syst Rev 2018
![Page 18: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/18.jpg)
Primary outcome: reducing treatment failure
• Moderate exacerbations• Low quality data: RR 0.72 (95%CI, 0.56 to 94)
1. Vollenweider et al. Cochrane Database Syst Rev 2018
![Page 19: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/19.jpg)
Primary outcome: reducing treatment failure
• Moderate exacerbations• Low quality data: RR 0.72 (95%CI, 0.56 to 94)
• Severe exacerbations• Moderate quality data: RR 0.65 (95%CI 0.38-1.12)
• Significance just reached if trials using older and no longer in clinical use (RR 0.76, 95%CI 0.58-1.00)
1. Vollenweider et al. Cochrane Database Syst Rev 2018
![Page 20: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/20.jpg)
Primary outcome: reducing treatment failure
• Moderate exacerbations• Low quality data: RR 0.72 (95%CI, 0.56 to 94)
• Severe exacerbations• Moderate quality data: RR 0.65 (95%CI 0.38-1.12)
• Significance just reached if trials using older and no longer in clinical use (RR 0.76, 95%CI 0.58-1.00)
• ICU related exacerbations• 1 trial: RR 0.19 (95%CI 0.08-0.45)
1. Vollenweider et al. Cochrane Database Syst Rev 2018
![Page 21: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/21.jpg)
Secondary outcomes
• Mortality and length of stay effect seen only in ICU treated exacerbations
1. Vollenweider et al. Cochrane Database Syst Rev 2018
![Page 22: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/22.jpg)
Secondary outcomes
• Mortality and length of stay effect seen only in ICU treated exacerbations
• No effect on mortality or length of hospital stay in out-patient and in-patient exacerbations
1. Vollenweider et al. Cochrane Database Syst Rev 2018
![Page 23: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/23.jpg)
Secondary outcomes
• Mortality and length of stay effect seen only in ICU treated exacerbations
• No effect on mortality or length of hospital stay in out-patient and in-patient exacerbations
• No studies have examined health reported outcomes
1. Vollenweider et al. Cochrane Database Syst Rev 2018
![Page 24: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/24.jpg)
Treatment with OCS
• Established in guidance for asthma and COPD exacerbations• Prescribed to prevent treatment failure in COPD1
1. Walters et al. Cochrane Syst Review 2009
![Page 25: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/25.jpg)
SCS for COPD exacerbations
• Primary outcomes• Treatment failure• HR 0.78 (0.63 – 0.97)
Walters et al. Cochrane Syst Review 2009
![Page 26: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/26.jpg)
SCS for COPD exacerbations
• Primary outcomes• Treatment failure• HR 0.78 (0.63 – 0.97)
• Secondary outcomes• Improve FEV1 and symptoms (72 hours)
• 140mls (90 to 190)
Walters et al. Cochrane Syst Review 2009
![Page 27: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/27.jpg)
SCS for COPD exacerbations
• Primary outcomes• Treatment failure• HR 0.78 (0.63 – 0.97)
• Secondary outcomes• Improve FEV1 and symptoms (72 hours)
• 140mls (90 to 190)
• Reduces length of stay by 1.22 days
• 95% CI 0.18 – 2.26
Walters et al. Cochrane Syst Review 2009
![Page 28: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/28.jpg)
CS in COPD attacks to prevent treatment failure
Walters et al, Cochrane Syst Review 2009
8 Studies; 2 out of 8 were positive for studied outcome.• Bullard et al. Single Centre ED study in Taiwan. IV Hydrocortisone 100mg QDS
followed by 4 days IV (if admitted) or OCS if discharged vs. placebo• Thompson et al. Single centre VA (OPD and ED). 340 screened. 27 randomised.
60mg OCS 3/7, 40mg OCS for 3/7 then 20mg OCS for 3/7 vs. Vit B6
![Page 29: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/29.jpg)
Cochrane conclusions
• COPD1
1. Walters, et al. Cochrane 2014
![Page 30: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/30.jpg)
Systemic corticosteroids are associated with harm
• COPD exacerbations1:• NNT to prevent 1 treatment failure is 10
1. Walters et al. Cochrane Syst Review 2009
![Page 31: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/31.jpg)
Systemic corticosteroids are associated with harm
• COPD exacerbations1:• NNT to prevent 1 treatment failure is 10
• But NNH is 5
1. Walters et al. Cochrane Syst Review 2009
![Page 32: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/32.jpg)
Systemic corticosteroids are associated with harm
• COPD exacerbations1:• NNT to prevent 1 treatment failure is 10
• But NNH is 5
• Acute illness2:• Increased risk of Sepsis (5x), VTE (3x) and Fracture (2x)
1. Walters et al. Cochrane Syst Review 2009; 2. Waljee et al. BMJ 2018
![Page 33: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/33.jpg)
Identification of the antibiotic responder: Is it possible?
![Page 34: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/34.jpg)
Stockley et al. Chest 2000
SPUTUM PURULENCE
![Page 35: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/35.jpg)
PROCALCITONIN
Sager. BMC Medicine 2017
![Page 36: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/36.jpg)
Daniels et al. AJRCCM 2010
C REACTIVE PROTEIN
![Page 37: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/37.jpg)
Summary
• Markers to identify who may need antibiotics have potential• CRP, purulence and purulence
• Need to be tested in prospective trials
• Evidence for antibiotics in COPD exacerbations don’t show benefit in all patients• Maybe important to identify those who need it and in whom there will be a response
![Page 38: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/38.jpg)
Identification of the steroid responder: Is it possible?
![Page 39: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/39.jpg)
Specific biomarkers to identify exacerbation clusters
Bafadhel et al. AJRCCM 2011: 184: 662-71
![Page 40: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/40.jpg)
Airway eosinophilic exacerbations
Sputum eosinophilia (≥3%) present in approximately 1/3rd of exacerbations
Sputum eosinophil (%)≥3 <3
-0.3
-0.2
-0.1
0.0
∆ F
EV
1(L
)
Absolute FEV1 change
from baselinep=0.026
Absolute CRQ score change
from baseline
Sputum eosinophil (%)≥3 <3
-2.0
-1.5
-0.5
0.0
∆ C
RQ
(u
nit
s)
p=0.003
-1.0
Bafadhel et al. AJRCCM 2011: 184: 662-71
![Page 41: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/41.jpg)
Response to steroids at exacerbation
So
ter ,
2013
Bafa
dh
el , 2011
0 .0
0 .2
0 .4
0 .6
0 .8
S tu d ie s
de
lta
FE
V (
L)
m e a n ( S D )
1. Soter et al. Inflammation 2013;36: 1178-85; 2. Bafadhel et al Am J Resp Crit Care Med 2011 184: 662-71
Sputum Eosinophils
≥3% <3%
Sputum Eosinophils
≥3% <3%
![Page 42: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/42.jpg)
Length of stay reduced in eosinophilic exacerbations treated with corticosteroids
Mean length of stay
5.0 days (1-19)
vs.
6.5 days (1-13)
Bafadhel M. Chest 2016
![Page 43: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/43.jpg)
Summary
• Eosinophilic exacerbations are common• Patients have bigger deficit in lung function
• Best response to SCS
![Page 44: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/44.jpg)
4. Emerging futures
![Page 45: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/45.jpg)
1. Redefine the acute event i. Use objective markers
2. Treatment stratificationi. Includes new treatments?
ii. Include repurposing of existing treatment
iii. Offering continuous treatment
![Page 46: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/46.jpg)
1. Goal to redefine the event
New proposal is to call these deterioration events1
COPD crisis
Crisis is defined as
‘a time of disagreement, confusion or suffering’, ‘an extremely difficult or dangerous point in a situation’ and ‘a moment during a serious illness when there is the possibility of suddenly getting either better or worse’
1. Bafadhel et al. Lancet Respir Med 2019. In Press
![Page 47: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/47.jpg)
1. Goal to redefine the event
New proposal is to call these deterioration events1
COPD crisis
Crisis is defined as
‘a time of disagreement, confusion or suffering’, ‘an extremely difficult or dangerous point in a situation’ and ‘a moment during a serious illness when there is the possibility of suddenly getting either better or worse’.
1. Bafadhel et al. Lancet Respir Med 2019. In Press
![Page 48: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/48.jpg)
A new definition – The COPD Crisis1
• Crisis first coined by Hippocrates
• The turning point in the illness at which the patient or the disease prevails
1. Bafadhel et al. Lancet Respir Med 2019. In Press
![Page 49: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/49.jpg)
A new definition – The COPD Crisis1
• Crisis first coined by Hippocrates
• The turning point in the illness at which the patient or the disease prevails
• Proposal• The crisis requires a temporal association
• Acute, protracted, resolving
• The crisis requires an underlying cause
1. Bafadhel et al. Lancet Respir Med 2019. In Press
![Page 50: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/50.jpg)
A new definition – The COPD Crisis1
• Crisis first coined by Hippocrates
• The turning point in the illness at which the patient or the disease prevails
• Proposal• The crisis requires a temporal association
• Acute, protracted, resolving
• The crisis requires an underlying cause
1. Bafadhel et al. Lancet Respir Med 2019. In Press
COPD Crisis Temporal association Potential underlying cause (known/unknown)*
potential,
confirmed
rapid, sub-acute, protracted,
resolving
virus, bacteria, cardiac dysfunction, anxiety, social
isolation
![Page 51: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/51.jpg)
2. Goal to target therapy in exacerbations
• STARR2 • Phase 4 multi-centre randomised clinical trial
• Near patient eosinophil testing for exacerbations of COPD)
• Study if eosinophil directed OCS is superior to standard care• Read-out Feb 2020
![Page 52: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/52.jpg)
2. Goal to use new treatment at exacerbation events
• Utilise biological clusters to drive treatment algorithms• Antibiotic stewardship
• Novel treatments • Old therapies, new indication
• New treatments
• Acute exacerbations treated with BenRAlizumab
![Page 53: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/53.jpg)
2. Goal to continue treatment following acute events
• Non-invasive ventilation• Improves outcomes
• Evidence demonstrates reduced mortality, reduced infections, reduced IV rates
• HOT HMV study1 – possible reduction in readmissions if Home NIV and O2 given to patients with persistent hypercapnia following discharge with acute exacerbation
1. Murphy et al,. JAMA. 2017 Jun 6; 317(21): 2177–2186
![Page 54: Management of acute exacerbations of COPD in 2020](https://reader031.vdocuments.us/reader031/viewer/2022012019/61687011d394e9041f6f9461/html5/thumbnails/54.jpg)
Conclusions
• The acute deteriorations of COPD are important events
• Defining these events could improve care • Rheumatology: monoclonal antibodies and OCS reduction
• Cardiology: risk scores in clinical practice
• Oncology: targeted treatment
• Understanding the COPD crisis (exacerbations) is developing • Over this new decade we should be in position to improve outcomes